Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.32 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3237864 | 0.93 | FAAH (0.33) | KDM4EALDH1A1GLAGAASLC9A1 | |
| SCHEMBL8908265 | 0.79 | SLC9A1 (0.32) | SLC9A1KCNA3 | |
| SCHEMBL4271660 | 0.79 | SLC9A1 (0.32) | SLC9A1KCNA3 | |
| SCHEMBL10402043 | 0.79 | CALM1 (0.35) | ALDH1A1 | |
| SCHEMBL3228612 | 0.77 | MGAM (0.43) | SLC9A1KCNA3 | |
| SCHEMBL3238058 | 0.77 | ESR1 (0.34) | SLC9A1KCNA3 | |
| SCHEMBL6841739 | 0.77 | ALDH1A1 (0.32) | KDM4EALDH1A1GLAGAASLC9A1 | |
| SCHEMBL10629120 | 0.76 | TDP1 (0.37) | ALDH1A1GAA | |
| SCHEMBL7139123 | 0.76 | HDAC3 (0.39) | ALDH1A1 | |
| SCHEMBL8986065 | 0.76 | TDP1 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069330-A1 | Pharmaceutical Compositions and Methods for Preparing and Using Lipophilic Organosulfur Cell Proliferation Inhibitors | Gately, Stephen (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2008147814-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PREPARING AND USING LIPOPHILIC ORGANOSULFUR CELL PROLIFERATION INHIBITORS | SILAMED, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069330-A1 | Pharmaceutical Compositions and Methods for Preparing and Using Lipophilic Organosulfur Cell Proliferation Inhibitors | SI, SLCO2B1, SLCO1B1 | KDM4E 1727/4885ALDH1A1 1781/4885GLA 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.